Porton Biologics

Porton Biologics operates as a subsidiary of Porton Pharma Solutions, a Contract Development and Manufacturing Organization (CDMO) founded in 2005. Porton Biologics itself was established in 2018 and is located in Suzhou Industrial Park, China. The parent company, Porton Pharma Solutions, was co-founded by Chairman and CEO Oliver (Nianfeng) Ju, Hui Chen, and Weiqiang Yang. A significant milestone for Porton Biologics was the closing of a Series A funding round in April 2021, which raised 400 million RMB to be used for the construction and operation of a Phase II commercial production facility.

The company functions as a CDMO platform, providing comprehensive, one-stop drug development and manufacturing services for biologics and conjugates. Its business model is centered on offering end-to-end services that span from early-stage research and preclinical development to clinical trials and commercial production. Porton Biologics serves a global clientele of pharmaceutical companies and biotechs, assisting them in advancing their drug candidates through the clinical pipeline and to the market. Revenue is generated by providing these integrated services for various drug modalities.

The core of Porton Biologics' offering is its integrated service platform for gene and cell therapies, as well as complex biologics. This includes services for plasmids, viral vectors, and various cell therapies. The company's capabilities cover the entire lifecycle, including process development, analytical method development, GMP manufacturing, quality control and release testing, and stability studies. Specifically, their services extend to biologics and conjugates like Antibody-Drug Conjugates (ADCs), Antibody-Oligonucleotide Conjugates (AOCs), and Peptide-Drug Conjugates (PDCs). The platform supports everything from payload-linker process development and manufacturing to conjugation and purification process development, and finally, drug substance and drug product manufacturing, including fill and finish operations.

Keywords: Contract Development and Manufacturing Organization, CDMO, biologics, gene therapy, cell therapy, drug development, pharmaceutical manufacturing, GMP production, viral vectors, plasmids, antibody-drug conjugates, ADC, process development, clinical trials, commercial production, pharmaceutical services, Suzhou, biopharmaceutical, end-to-end services, drug substance manufacturing